- Home
- LVTX
as 04-18-2025 1:39pm EST
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
| Founded: | 2016 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 34.2M | IPO Year: | 2021 |
| Target Price: | $3.17 | AVG Volume (30 days): | 61.1K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $3.20 | Next Earning Date: | 05-20-2025 |
| Revenue: | $11,982,000 | Revenue Growth: | 77.01% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest LAVA Therapeutics N.V. News
LVTX Breaking Stock News: Dive into LVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
GlobeNewswire
22 days ago
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
2 months ago
LAVA Announces Evaluation of Strategic Options
GlobeNewswire
3 months ago
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
GlobeNewswire
4 months ago
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
GlobeNewswire
8 months ago
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
8 months ago
LAVA Reports Second Quarter 2024 Financial Results and Business Update
GlobeNewswire
10 months ago
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Compare LVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LVTX LAVA Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.